Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/aje/kwae258 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of Clazosentan and Nimodipine on Vasospasm and Vasospasm-Related Outcomes after Aneurysmal Subarachnoid Hemorrhage : A Post-hoc Propensity Score-Matched Analysis of Six Randomized Clinical Trials.
J Korean Neurosurg Soc
January 2025
Department of Neurosurgery, Bucheon St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
Objective: Clazosentan is a recently approved endothelin receptor antagonist indicated for the prevention of vasospasm and related complications following aneurysmal subarachnoid hemorrhage (aSAH). To date, no direct, head-to-head comparison between clazosentan and nimodipine has been conducted. In this study, we indirectly assessed the efficacy and safety of these two drugs in preventing vasospasm and its associated outcomes after aSAH.
View Article and Find Full Text PDFStatin Use With Immune Checkpoint Inhibitors and Survival in Nonsmall Cell Lung Cancer.
Clin Lung Cancer
December 2024
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
Objective: To determine the association between concurrent statin use with immune checkpoint inhibitors (ICIs) and lung cancer-specific and overall mortality in patients with nonsmall cell lung cancer (NSCLC).
Materials And Methods: SEER-Medicare was used to conduct a retrospective study of Medicare beneficiaries ≥65 years of age diagnosed with NSCLC between 2007 and 2017 treated with an ICI. Patients were followed from date of first ICI claim until death, 1 month from last ICI claim, or 12/31/2018, whichever came first.
In-hospital mortality and risk factors in critically ill patients with hypertrophic cardiomyopathy.
J Cardiol
January 2025
Department of Cardiology, St. Luke's University Health Network, Bethlehem, PA, USA. Electronic address:
Background: Hypertrophic cardiomyopathy (HCM) is a common genetic disease with estimated prevalence of 0.2-0.5 %.
View Article and Find Full Text PDFClinical Outcomes after Transcatheter Aortic Valve Implantation in Nonagenarian Patients: a Retrospective Population-Based Cohort Study.
Ann Epidemiol
January 2025
IRCCS Centro Cardiologico Monzino, Department of Cardiovascular Surgery, 20138 Milan, Italy; Department of Biomedical, Surgical and Dental Sciences, University of Milan, 20100 Milan, Italy.
Purpose: To compare the overall survival and the risk of all-cause and heart failure-specific hospitalization in nonagenarian patients hospitalized for symptomatic severe aortic stenosis (AS) who underwent transcatheter aortic valve implantation (TAVI) or conservative treatment.
Methods: Population-based retrospective cohort study based on healthcare utilization databases of the Italian region of Lombardy. The cohort included all nonagenarians hospitalized for AS between 2017 and 2021, who underwent TAVI within 90 days from first diagnosis or conservative treatment.
Association of rapid response system with clinical outcomes after surgery under general anesthesia.
J Clin Anesth
January 2025
Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea; Department of Anesthesiology and Pain Medicine, College of Medicine, Seoul National University, Seoul, South Korea. Electronic address:
Background: In this population-based cohort study involving a nationwide database from South Korea, we aimed to determine whether rapid response system (RRS) implementation is associated with mortality and morbidity after surgery under general anesthesia.
Methods: Patients who underwent surgery under general anesthesia at the hospital between January 1, 2021, and December 31, 2021. Patients admitted to hospitals with an RRS were categorized into the RRS group, whereas those without an RRS were categorized into the non-RRS group.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!